BPC-157 vs TB-500: Complete Comparison
Two of the most researched tissue repair peptides — different mechanisms, different timelines, and why the Wolverine Stack combines both for comprehensive coverage.
BPC-157: The Vascular Builder
BPC-157 (Body Protection Compound-157) is a 15 amino acid synthetic peptide (MW: 1419.55 Da, CAS: 137525-51-0) derived from a protective protein found in human gastric juice. It has been studied extensively by Dr. Predrag Sikiric at the University of Zagreb across 36+ preclinical studies spanning musculoskeletal repair, gut healing, and systemic effects. Unlike most peptides, no minimum toxic dose has been identified in any study to date.
BPC-157 — Three Core Pathways
Stimulates new blood vessel formation in damaged tissue — critical for nutrient delivery to repair sites.
Stabilizes nitric oxide production for sustained vascular integrity and endothelial health.
Accelerates fibroblast migration to injury sites — directly speeds collagen deposition and structural repair.
Key BPC-157 Research
BPC-157 Research Dosing Protocol
6–8 hour half-life supports localized injection near injury site for targeted action. Subcutaneous or intramuscular administration.
TB-500: The Systemic Mobilizer
TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a 43 amino acid protein (CAS: 77591-33-4) that constitutes 40–50% of the total intracellular G-actin pool. While BPC-157 operates primarily through vascular and growth factor signaling, TB-500's primary mechanism is cytoskeletal — regulating actin dynamics to enable cell migration across tissue compartments. Its ~10 day half-life gives it fundamentally different kinetics: less frequent dosing, more systemic distribution.
TB-500 — Three Core Pathways
Sequesters 40–50% of total intracellular G-actin pool, enabling rapid cytoskeletal remodeling during cell migration to injury sites.
Integrin-linked kinase (ILK) activation promotes cell survival signaling and integrin-mediated attachment at repair sites.
MMP-2 upregulation enables extracellular matrix remodeling — removes damaged collagen scaffold and creates space for new tissue architecture.
Key TB-500 Research
TB-500 Research Dosing Protocol
~10 day half-life enables less frequent dosing vs BPC-157. Subcutaneous administration. Systemic distribution means injection site is less critical.
Get the Wolverine Stack — BPC-157 + TB-500
Research-grade BPC-157 and TB-500 from Apollo Peptide Sciences — the most studied tissue repair peptide combination.
Head-to-Head Comparison
| Property | BPC-157 | TB-500 |
|---|---|---|
| Structure | 15 amino acids, 1419.55 Da | 43 amino acids, thymosin β4 fragment |
| CAS Number | 137525-51-0 | 77591-33-4 |
| Primary Mechanism | Angiogenesis (VEGFR2/eNOS) | Actin sequestration / cytoskeletal |
| Half-Life | 6–8 hours | ~10 days |
| Dosing Frequency | 1–2x daily | 2x/week → 1x/week |
| Dose per Admin | 250–500 mcg | 2–5 mg |
| Injection Site | Near injury (localized) | Any SC site (systemic) |
| Cell Recruitment | VEGF → endothelial cells | Actin → all migratory cells |
| Anti-Inflammatory | Indirect (vascular) | Direct cytokine modulation |
| Study Count | 36+ (Sikiric lab) | Multiple (cardiac, corneal, hair) |
| Toxic Dose | None identified | None identified |
| Price (Apollo) | $59.99 / 10mg | $59.99 / 10mg |
Why Stack Them: The Wolverine Rationale
BPC-157 and TB-500 address different phases of tissue repair. Together they cover the full cascade.
- → Stimulates VEGF-dependent new blood vessel formation
- → Establishes nutrient/oxygen delivery to repair site
- → Fibroblast migration via FAK-paxillin — starts collagen deposition
- → Upregulates EGF and FGF for cellular proliferation
- → Localized injection concentrates action at injury site
- → Actin sequestration enables all migratory cell types to reach injury
- → Stem cells, immune cells, fibroblasts — systemic mobilization
- → ILK activation supports cell survival at repair site
- → MMP-2 clears damaged ECM for clean scaffold
- → Systemic distribution covers multiple injury sites simultaneously
Wolverine Stack Protocol
- → 250–500 mcg, 1–2x daily
- → Inject near injury site (SC or IM)
- → 4–8 week cycle
- → Morning + evening for acute injury
- → 2–5 mg per injection
- → 2x/week for 4 weeks (loading), then 1x/week
- → Any SC injection site
- → 4–8 week cycle, aligned with BPC-157
Which to Choose?
- ✓Specific localized injury (tendon, ligament, muscle tear)
- ✓Gut or GI healing is a priority
- ✓You want targeted injection near the site
- ✓Budget is limited — most study coverage
- ✓Acute injury in early stages
- ✓Multiple or diffuse injury sites
- ✓Systemic recovery (full body, cardiac, neurological)
- ✓Less frequent dosing is preferred
- ✓Hair growth / skin repair is a goal
- ✓Chronic inflammation management
- ✓Serious soft tissue injury
- ✓Maximum recovery speed is priority
- ✓Comprehensive tissue repair protocol
- ✓Both local and systemic coverage desired
- ✓Budget allows $119.98 for the pair
Frequently Asked Questions
BPC-157 and TB-500 can be combined in the same syringe for injection — they are chemically compatible in reconstituted solution. However, many researchers prefer separate injections to maintain BPC-157 closer to the injury site (localized) while TB-500 is administered subcutaneously anywhere for systemic distribution.
BPC-157 has a 6–8 hour half-life due to its smaller size (15 AA) and rapid enzymatic clearance. TB-500 at 43 amino acids has a much longer ~10 day half-life, meaning a single injection maintains therapeutic levels for up to two weeks. BPC-157's short half-life is actually advantageous for localized action — it concentrates effects at the injection site rather than distributing systemically.
Preclinical evidence suggests complementary and potentially synergistic effects. BPC-157 drives angiogenesis via VEGFR2, establishing the vascular network. TB-500 mobilizes repair cells via actin sequestration, populating the new vasculature BPC-157 creates. The mechanisms are non-overlapping across different signaling pathways, suggesting additive benefit with low risk of interference.
TB-500 is a synthetic peptide corresponding to the active fragment of Thymosin Beta-4 (amino acids 17–23 of Tβ4). Full-length Tβ4 is 43 amino acids; TB-500 is the shorter active sequence responsible for actin-binding activity. TB-500 is used in research because it is more cost-effective to synthesize and demonstrates equivalent actin-sequestration activity to the full protein.
In preclinical models, BPC-157 shows measurable angiogenic effects within 48–72 hours of administration. Structural tissue repair — collagen deposition, functional load recovery — typically shows significant improvement at 2–4 weeks. TB-500 mobilizes cells systemically within days; observable tissue repair effects are typically documented at 2–6 weeks depending on injury severity and tissue type.
The Wolverine Stack is the combination of BPC-157 + TB-500, named after the Marvel character's famous regenerative healing ability. It became the most popular peptide combination in the bodybuilding and injury recovery research community because the two peptides cover complementary aspects of tissue repair: BPC-157 for vascular infrastructure and fibroblast recruitment, TB-500 for systemic cell mobilization and ECM remodeling. Total cost: $119.98 for 10mg of each from Apollo.
Build the Wolverine Stack
Research-grade BPC-157 + TB-500 from Apollo Peptide Sciences. The most studied tissue repair peptide combination — $119.98 for both 10mg vials.